On November 22, 2024, the pan-Canadian Pharmaceutical Alliance (pCPA) released its 2023-2024 impact report.
According to the pCPA, estimated dollar savings for public drug plans from pCPA negotiations were $4.63 billion ($3.72 billion on brand-name drugs and $0.91 billion on generic drugs), an increase from the estimated $3.89 billion in 2022-2023.
The pCPA also reports there were 41 total negotiations with public drug plans, up by more than 50% from pre-pandemic levels.
The impact report highlights initiatives from 2023-2024, including:
- pCPA Temporary Access Process (pTAP): the pTAP negotiation pathway (see our article) applies to drugs that follow the time-limited reimbursement pathway from Canada’s Drug Agency, ultimately allowing patients to have temporary access to new therapies with conditional approval.
- Three-year pricing initiative for generic drugs: the pricing initiative for generic drugs, the pan-Canadian Tiered Pricing Framework (TPF) (see our article), was renewed and is in effect until 2026.
- New tools: economic insight packages and the negotiation pipeline were introduced to “strengthen negotiations and broaden [the pCPA’s] set of indicators for measuring the impact of the pCPA.”
[View source.]
